• Molecular NameCarboprost Tromethamine
  • SynonymNA
  • Weight368.514
  • Drugbank_IDDB00429
  • ACS_NO58551-69-2
  • Show 2D model
  • LogP (experiment)2.578
  • LogP (predicted, AB/LogP v2.0)3.15
  • pkaN/A
  • LogD (pH=7, predicted)1.05
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.07
  • LogSw (predicted, AB/LogsW2.0)0.35
  • Sw (mg/ml) (predicted, ACD/Labs)0.22
  • No.of HBond Donors4
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds12
  • TPSA97.99
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA synthetic prostaglandin analogue of PGF2α (specifically, it is 15-methyl-PGF2α) with oxytocic properties.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized in the lungs and liver. Metabolites are excreted in urine.
  • Half life10~20 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include irritation, nausea, vomiting, diarrhea, coughing, dyspnea, asthma, hypertension, flushing, and pyrexia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A